Last updated: March 12, 2024
Sponsor: Maasstad Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Sarcopenia
Treatment
Placebo
Protein drink supplementation
Clinical Study ID
NCT05570474
L2022059
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Scheduled for a laparoscopic Roux-en-Y Gastric Bypass
- Age 18 - 65 years
- Body Mass Index ≥ 35 with the presence of severe comorbidity related to morbid obesity (diabetes mellitus type 2, obstructive sleep apnoea syndrome (OSAS), hypertension,etc.) or a BMI ≥ 40 with or without the presence of severe comorbidity related tomorbid obesity
- Written informed consent
Exclusion
Exclusion Criteria:
- Revisional bariatric surgery
- A protein-restricted diet for medical reasons
- Diagnosis of a (neuro-) muscular disease
- Inability to undergo MF-BIA (i.e. pregnancy, pacemaker)
- Allergy to any of the ingredients of either the protein or the placebo shake
Study Design
Total Participants: 266
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
September 01, 2022
Estimated Completion Date:
December 01, 2024
Study Description
Connect with a study center
Maasstad Hospital
Rotterdam, Zuid Holland 3079DZ
NetherlandsActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.